-31.4%
RIVN vs GSK
+47.2%
-78.6%
-65.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.3% | -1.0% | +1.3% | +0.4% |
| 7D | +0.9% | -5.4% | +6.3% | +1.5% |
| 30D | -1.9% | -4.6% | +2.7% | -1.4% |
| 3M | +8.7% | -5.1% | +13.9% | +9.3% |
| 6M | -3.0% | -11.4% | +8.5% | -1.8% |
| YTD | -18.6% | +0.7% | -19.3% | -18.7% |
| 1Y | +15.4% | +23.0% | -7.6% | +13.3% |
| All | -31.4% | +47.2% | -78.6% | -38.0% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling